Literature DB >> 18417998

Screening advances and diagnostic choice: the problem of residual risk.

George P Henry1, David W Britt, Mark I Evans.   

Abstract

OBJECTIVE: Over the past decade some authorities have suggested that advanced screening methodologies obviate the need for more invasive, diagnostic procedures. Data on Down syndrome (DS) births for Colorado from 1989 to 2005 were used to examine the implications of a decreasing use of amniocentesis.
METHODS: Publicly available, State of Colorado Department of Public Health data on DS birth rates for women were compared to amniocentesis use at Colorado's largest prenatal diagnostic center. Longitudinal changes on DS birth rates by maternal age (>35 and <35), and utilization of amniocentesis.
RESULTS: In Colorado, from 1989 to 2005, the rate for DS births for women 35+ rose considerably, while <35, rates remained stable (Cochran-Armitage test, p < 0.001). An autocorrelation-corrected test yielded a significant negative relationship between amniocentesis use (in 1,000 s) and AMA DS rates (b = -11.30; p < 0.006; DW = 1.55). Confounding explanations involving sampling problems, socio-demographic factors, political conservatism and prevention orientation do not appear to account for these results.
CONCLUSIONS: Replacement of definitive diagnosis with screening tests must be implemented with caution, particularly when using technologies with wide individual operator-dependent variability. Screening paradigms when performed with accuracy can markedly improve assessment of risks, but caution must be used in presenting negative screening results to women who still have a relatively high residual risk after a negative screen, and more generally in the displacement of technologies that provide definitive answers. (c) 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2008        PMID: 18417998     DOI: 10.1159/000123619

Source DB:  PubMed          Journal:  Fetal Diagn Ther        ISSN: 1015-3837            Impact factor:   2.587


  4 in total

1.  The feasibility study of non-invasive fetal trisomy 18 and 21 detection with semiconductor sequencing platform.

Authors:  Young Joo Jeon; Yulin Zhou; Yihan Li; Qiwei Guo; Jinchun Chen; Shengmao Quan; Ahong Zhang; Hailing Zheng; Xingqiang Zhu; Jin Lin; Huan Xu; Ayang Wu; Sin-Gi Park; Byung Chul Kim; Hee Jae Joo; Hongliang Chen; Jong Bhak
Journal:  PLoS One       Date:  2014-10-20       Impact factor: 3.240

2.  Should advanced maternal age be a reasonable indication for invasive diagnostic testing?

Authors:  Hyun Mee Ryu
Journal:  Obstet Gynecol Sci       Date:  2013-05-16

3.  Maternal age-specific rates of fetal chromosomal abnormalities in Korean pregnant women of advanced maternal age.

Authors:  Young Joo Kim; Jee Eun Lee; Soo Hyun Kim; Sung Shin Shim; Dong Hyun Cha
Journal:  Obstet Gynecol Sci       Date:  2013-05-16

4.  Comparison of two high-throughput semiconductor chip sequencing platforms in noninvasive prenatal testing for Down syndrome in early pregnancy.

Authors:  Sunshin Kim; HeeJung Jung; Sung Hee Han; SeungJae Lee; JeongSub Kwon; Min Gyun Kim; Hyungsik Chu; Hongliang Chen; Kyudong Han; Hwanjong Kwak; Sunghoon Park; Hee Jae Joo; Byung Chul Kim; Jong Bhak
Journal:  BMC Med Genomics       Date:  2016-04-30       Impact factor: 3.063

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.